Top

Published in:

01-03-2014 | Therapeutic Trials (B Pitt, Section Editor)

Should Patients with Obesity and Hypertension be Treated Differently from Those Who Are Not Obese?

Authors: Michael J. Bloch, Anthony J. Viera

Published in: Current Hypertension Reports | Issue 3/2014

Abstract

Obesity and hypertension frequently coexist. Measuring blood pressure (BP) accurately in obese patients is challenging and may require strategies that are less accurate, such as forearm cuffing or use of wrist cuffs. Pathophysiologic mechanisms of hypertension may differ between obese and non-obese individuals, which may result in differing effects of common BP-lowering medications. However, to date, there is insufficient trial data to recommend a different approach to medication selection based on body mass index. Additionally, the goal BP is generally not different between obese and non-obese patients. Weight loss should be emphasized for obese patients with hypertension, and interventions in addition to diet and exercise may include weight loss medications and bariatric surgery. Recognition and treatment of obstructive sleep apnea is also important.

Centers for Disease Control. Healthy weight, overweight, and obesity among U.S. adults. National Health and Nutrition Examination Survey. Available at: http://www.cdc.gov/nchs/data/nhanes/databriefs/adultweight.pdf. Accessed Nov 7, 2013

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. NCHS Data Brief. 2013;131:1–8.PubMed

Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82.PubMedCrossRef

Quesenberry Jr CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med. 1998;158:466–72.PubMedCrossRef

Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body mass index and future healthcare costs: a retrospective cohort study. Obes Res. 2001;9:210–8.PubMedCrossRef

Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood). 2003 Jan-Jun;Suppl Web Exclusives:W3–219–26.

Landsberg L, Aronne LJ, Beilin L, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment. A position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15:14–33. Reviews the pathophysiology of obesity-related hypertension and provides recommendations for management, including medical treatments for obesity.CrossRef

Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010;23(11):1170–8.PubMedCrossRef

Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord. 2002;26(1):48–57.PubMedCrossRef

10.

Graves JW, Bailey KR, Sheps SG. The changing distribution of arm circumferences in NHANES III and NHANES 2000 and its impact on the utility of the 'standard adult' blood pressure cuff. Blood Press Monit. 2003;8(6):223–7.PubMedCrossRef

11.

Ostchega Y, Huges JP, Zhang G, et al. Mean mid-arm circumference and blood pressure cuff sizes for US adults: National Health and Nutrition Examination Survey, 1999-2010. Blood Press Monit. 2013;18(3):138–43. This report from the NHANES observational study suggests that 42.9% of men and 25.3% of women require a large cuff for accurate BP measurement. PubMedCrossRef

12.

Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood Pressure Measurement in Humans: A Statement for Professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–61.PubMedCrossRef

13.

Palatini P, Parati G. Blood pressure measurement in very obese patients: A challenging problem. J Hypertens. 2011;29:425–9. This seminal article remains the most comprehensive summary of recommendations for BP measurement. Office, home, and ambulatory BP measurement are all covered, with emphasis on practical recommendations. PubMedCrossRef

14.

Bonso E, Saladini F, Zanier A, et al. Accuracy of a single rigid conical cuff with standard size bladder coupled to an automated oscillometric device over a wide range of arm circumferences. Hypertens Res. 2010;33:1186–91.PubMedCrossRef

15.

Mourad JJ, Lopez-Sublet M, Aoun-Bahous S, et al. Impact of miscuffing during home blood pressure measurement on the prevalence of masked hypertension. Am J Hypertens. 2013;26(10):1205–9.PubMedCrossRef

16.

Maxwell GF, Prujit JF, Amtzenius AC. Comparison of conical cuff and the standard rectangular cuffs. Int J Epidemiol. 1985;14:468–72.PubMedCrossRef

17.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRef

18.

Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;25:343.

19.

Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–38. This article is one of the more recent guidelines for hypertension management. CrossRef

20.

Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm Jr RH, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780–800.PubMedCrossRef

21.

James PA, Oparil S, Carter BL, et al. Evidence Based Guidelines for the Management of High Blood Pressure in Adults: Report from the panel members appointed to the eighth joint national committee (JNC8). JAMA. 2013. doi:10.1001/jama.2013.284427.

22.

Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867–72.PubMedCrossRef

23.

Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120:863–70.PubMedCrossRef

24.

Wassertheil-Smoller S, Fann C, Allman RM, et al. Relation of low body mass to death and stroke in systolic hypertension in the elderly program. Arch Intern Med. 2000;160:494–500.PubMedCrossRef

25.

Weber MA, Jamerson K, Bakris G, et al. Effects of body size and hypertension treatment on cardiovascular event rates: subanalysis of the ACCOMPLISH randomized controlled trial. Lancet. 2013. This pre-specified analysis of the results of the ACCOMPLISH study suggests that the combination of an ACE inhibitor + a calcium channel blocker offers equal reduction in CV events in lean and obese patients, but that the combination of an ACE inhibitor + diuretic offers better reduction of CV events in overweight as opposed to lean individuals.

26.

Jamerson K, Weber MA, Bakris G, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Eng J Med. 2008;359:2417–28.CrossRef

27.

Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43(3):518–24.PubMedCrossRef

28.

Tirosh A, Garg R, Adler GK. Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome. Curr Hypertens Rep. 2010;12:252–7.PubMedCentralPubMedCrossRef

29.

de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertens. 2010;55:147–52.CrossRef

30.

Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertens. 2007;49:839–45.CrossRef

31.

ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA. 2002;288(23):2981–97.CrossRef

32.

Vgontzas AN, Tan TL, Bixler EO, Martin LF, Shubert D, Kales A. Sleep apnea and sleep disruption in obese patients. Arch Intern Med. 1994;154:1705–11.PubMedCrossRef

33.

Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg. 2003;13:676–83.PubMedCrossRef

34.

Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271–7.PubMedCrossRef

35.

Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography. Ann Intern Med. 2007;146:157–66.PubMedCrossRef

36.

Skomro RP, Gjevre J, Reid J, et al. Outcomes of home-based diagnosis and treatment of obstructive sleep apnea. Chest. 2010;138(2):257–63.PubMedCrossRef

37.

Yalamanchali S, Farajian V, Hamilton C, Pott TR, Samuelson CG, Friedman M. Diagnosis of obstructive sleep apnea by peripheral arterial tonometry: meta-analysis. JAMA Otolaryngol Head Neck Surg. 2013. doi:10.1001/jamaoto.2013.5338.PubMed

38.

Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003;107(1):68–73.PubMedCrossRef

39.

Alajmi M, Mulgrew AT, Fox J, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. Lung. 2007;185(2):67–72.PubMedCrossRef

40.

Somers VK, White DP, Ain R, et al. Sleep apnea and cardiovascular disease: An American heart association/American college of cardiology foundation scientific statement from the American heart association council for high blood pressure research professional education committee. J Am Coll Cardiol. 2008;5d2(8):686–717. This scientific statement suggests that the presence of OSA is closely associated with hypertension and other CV disease, but that the effect of CPAP on BP reduction in hypertensive patients with OSA is modest – on the order of about 3 mmHg systolic. CrossRef

41.

Martinez-Garcia MA, Capote F, Campos-Rodriguez F, et al. Effect of CPAP on blood pressure in patient with obstructive sleep apnea and resistant hypertension: The HIPARCO Randomized Clinical Trial. JAMA. 2013;310(22):2407–15.PubMed

42.

Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized trial. JAMA. 2012;307(20):2161–8.PubMedCrossRef

43.

Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.PubMedCrossRef

44.

Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20:2257–67.PubMedCrossRef

45.

Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. 2013;3:CD007654.PubMed

46.

Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMedCrossRef

47.

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.PubMedCrossRef

48.

Ricci C, Gaeta M, Rausa E, Macchitella Y, Bonavina L. Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6,587 patients. Obes Surg. 2013.

49.

Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013. doi:10.1001/jama.2013.280928. This recently published study highlights the weight loss and metabolic benefits at three years of weight loss achieved through bariatric surgery.

50.

Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.CrossRef

51.

Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9.CrossRef

Title: Should Patients with Obesity and Hypertension be Treated Differently from Those Who Are Not Obese?
Authors: Michael J. Bloch
Anthony J. Viera
Publication date: 01-03-2014
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 3/2014
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-014-0418-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

ACE2: Angiotensin II/Angiotensin-(1–7) Balance in Cardiac and Renal Injury

The Contribution of the ACCOMPLISH Trial to the Treatment of Stage 2 Hypertension

Late Hypertension in Patients with Repaired Aortic Coarctation

Is There a Role for the Incretin System in Blood Pressure Regulation?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials